Medical Device Oral Mucosa Irritation Testing: Standards, Methods, and Regulatory Applications

Oral mucosa irritation testing is an essential biocompatibility endpoint for medical devices that contact oral tissue, including dental appliances, orotracheal tubes, and buccal drug-delivery systems. Performed in accordance with ISO 10993-23 and the broader ISO 10993 series, this test evaluates whether device materials or their extracts induce erythema, edema, or inflammatory tissue changes in mucosal tissue. This article explains the applicable standards, sample preparation, testing methods, scoring criteria, and typical regulatory applications of the oral mucosa irritation test.

Technical Overview

Oral mucosa irritation testing is a localized biological safety evaluation designed to determine whether a medical device, its constituent materials, or substances leached from the device can provoke a reversible inflammatory response in oral mucosal tissue. It forms part of the overall biological evaluation of medical devices defined by the risk-management framework of ISO 10993-1, and it is specifically required for devices with direct or indirect contact with the oral cavity, pharyngeal mucosa, or related mucosal surfaces.

The primary governing standard is ISO 10993-23:2021, Biological evaluation of medical devices — Part 23: Tests for irritation, which superseded the irritation-testing requirements previously covered by ISO 10993-10. Supporting standards include ISO 10993-12 for sample preparation and reference materials, ISO 10993-2 for animal welfare requirements, and ISO 10993-1 for the evaluation and testing framework. In China, the corresponding requirements are addressed within the GB/T 16886 series, which is the national adoption of the ISO 10993 series, while other regions apply harmonized adoptions such as EN ISO 10993 for the European market.

A complete evaluation typically combines macroscopic observation of the mucosal reaction, such as erythema and edema, with microscopic histopathological examination of the mucosal tissue. Consistent with the principles of replacement, reduction, and refinement (the 3Rs), current editions of the standard promote a stepwise approach in which validated in vitro methods, such as reconstructed human oral epithelium models, are considered before in vivo testing.

Testing Samples

Devices and Materials Commonly Submitted

Any device or material whose intended use involves contact with oral or pharyngeal mucosa is a candidate for this test. Representative examples include:

• Denture base resins, denture relining materials, and acrylic prostheses
• Orthodontic brackets, arch wires, elastomeric ligatures, clear aligners, and retainers
• Dental cements, bonding agents, impression materials, and gingival retraction materials
• Orotracheal tubes, laryngeal mask airways, oral and nasal airways, bite blocks, and suction tips
• Buccal and sublingual drug-delivery systems and oral topical formulations
• Teethers, pacifier components intended for oral contact, dental floss, and interdental brushes

Sample Preparation Requirements

Sample preparation follows ISO 10993-12 and must use the final product in its clinically representative state, including the intended sterilization or cleaning process. Where testing of the intact device is impractical, test extracts are prepared using both a polar medium (such as physiological saline) and a non-polar medium (such as sesame or cottonseed oil), with additional media selected as justified by the device composition and clinical use.

Standard extraction parameters include surface-area-to-volume ratios such as 3 cm²/mL or 6 cm²/mL depending on material thickness, or gravimetric ratios (commonly 0.2 g/mL, or 0.1 g/mL for low-density porous materials) for irregularly shaped items. Common extraction conditions include 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, with the condition selected to simulate or exaggerate clinical exposure without degrading the material.

Control Materials

Each study includes appropriate controls to ensure validity. Negative controls typically consist of the blank extraction medium or an established inert reference material, while positive control substances with known mild irritant properties are used periodically to demonstrate the sensitivity of the test system, whether an animal model or an in vitro tissue model.

Testing Items

The oral mucosa irritation test evaluates a defined set of endpoints that together characterize the local tissue response. Typical test items include:

• Macroscopic scoring of erythema and eschar formation at the application site
• Macroscopic scoring of edema and swelling of the mucosal tissue
• Calculation of the mucosal irritation index based on the difference between test and control scores
• Histopathological assessment of mucosal tissue, including epithelial degeneration, erosion or ulceration, necrosis, inflammatory cell infiltration, intercellular edema, hyperkeratosis, and vascular congestion
• For in vitro models, quantitative endpoints such as tissue viability measured by MTT assay and release of inflammatory mediators such as interleukin-1 alpha, interleukin-6, and prostaglandin E2

Testing Methods

In Vivo Oral Mucosa Irritation Test

The conventional in vivo method applies the test article or its extracts repeatedly to the oral mucosa of a suitable animal model, such as the buccal mucosa of rabbits or the cheek pouch of hamsters. The exposure regimen, typically involving one or two applications per day over a study period of up to 14 days, is designed to mirror or reasonably exaggerate the intended clinical contact duration. Application sites are observed and scored daily for erythema and edema using a standardized grading scale from 0 to 4, and at the conclusion of the observation period the animals are humanely euthanized for necropsy and histopathological examination of the mucosal tissue. All procedures comply with the animal welfare requirements of ISO 10993-2 and applicable institutional ethics approvals.

Direct Contact Versus Extract Application

For devices that physically contact mucosa during clinical use, such as denture bases or orthodontic appliances, direct application of the material to the mucosal surface may be performed. For devices whose biological risk is driven primarily by leachable substances, extracts are applied to the mucosa, allowing evaluation of the irritant potential of soluble chemicals released from the device under simulated use conditions.

In Vitro Reconstructed Oral Epithelium Models

Three-dimensional reconstructed human oral epithelium (RhOE) tissue models are increasingly used as screening or replacement methods. The test substance or extract is applied to the apical surface of the tissue, and irritant potential is determined by measuring post-exposure tissue viability, commonly using an MTT conversion assay, with reduced viability below a defined threshold relative to the negative control indicating irritant potential. Cytokine release assays provide complementary mechanistic information. Where an in vitro result is negative and justified within the biological evaluation plan, in vivo testing may be reduced or waived in line with the stepwise strategy of ISO 10993-23.

Scoring and Interpretation

Results are interpreted by comparing mean macroscopic irritation scores between the test article and negative control sites at each observation interval, and by comparing histopathological findings in treated versus control tissue. A test article is generally considered non-irritant to the oral mucosa when the reaction does not significantly exceed that of the negative control and no treatment-related microscopic lesions are observed. Any elevation in erythema, edema, or histological inflammation indices must be evaluated within the overall risk assessment of the device.

Applications

Oral mucosa irritation test data are routinely included in biocompatibility packages supporting regulatory submissions in major jurisdictions, including premarket notifications and approvals in the United States, technical documentation under the European Medical Device Regulation, and registration dossiers in China and other markets that reference the ISO 10993 or GB/T 16886 series. The test supports demonstration of conformity with the biological evaluation requirements of the applicable quality management and risk management systems.

Beyond regulatory submission, the test is widely applied during research and development for screening novel polymers, resins, coatings, and adhesive formulations intended for oral contact. It is also used in change-control programs, for example when a material supplier, manufacturing process, or sterilization method is modified, in order to confirm that the biological safety profile of the device remains acceptable.

Typical product categories benefiting from this evaluation include dental prosthetic and orthodontic devices, airway management products, oral hygiene devices, oral drug-delivery platforms, and pediatric oral-care articles manufactured by medical device and consumer-health companies worldwide.

FAQ

When is oral mucosa irritation testing required?

Testing is required when a medical device contacts oral, pharyngeal, or other mucosal tissue during clinical use, as identified by the contact nature and duration categories of ISO 10993-1. Devices with limited, prolonged, or permanent mucosal contact generally warrant irritation evaluation as part of the biological evaluation plan.

Which standards govern the test?

The core standard is ISO 10993-23:2021 for irritation testing, supported by ISO 10993-12 for sample preparation, ISO 10993-2 for animal welfare, and ISO 10993-1 for the evaluation framework. In China, the GB/T 16886 series applies as the national adoption of ISO 10993, and EN ISO 10993 applies in Europe.

How are samples prepared for testing?

Samples are tested in their final, finished state whenever possible, including sterilization. Extracts are prepared in polar and non-polar media using standardized surface-area-to-volume or mass-to-volume ratios and extraction conditions defined in ISO 10993-12, selected to simulate or exaggerate clinical exposure.

Are animal tests always necessary?

No. ISO 10993-23 promotes a stepwise, 3Rs-compliant strategy. Validated in vitro methods, such as reconstructed human oral epithelium models, may be used first, and in vivo testing is conducted only when scientifically justified, such as when in vitro data are inconclusive or the material is not compatible with in vitro systems.

How is a passing result determined?

A non-irritant conclusion is supported when macroscopic erythema and edema scores, as well as histopathological findings, do not significantly differ from the negative control and no treatment-related tissue damage is observed. Results are always interpreted within the overall biological risk assessment of the device.

How long does a typical study take?

Depending on the extraction schedule, exposure duration, and histopathology workload, in vivo studies commonly require several weeks from sample receipt to final report, while in vitro screening studies can often be completed within a shorter timeframe. Accredited third-party laboratories can advise on study design and timelines based on the specific device and regulatory target markets.